|
pubmed:abstractText |
To determine the efficacy and safety of treating predominantly hemorrhagic age-related macular degeneration (AMD) with transconjunctival sutureless vitrectomy (TSV), tissue plasminogen activator (tPA), sulphur hexafluoride (SF6), and intravitreal bevacizumab.
|
|
pubmed:affiliation |
Institut de la Màcula i de la Retina, Department of Ophthalmology, Hospital Universitari de Bellvitge, Centro Médico Teknon, Barcelona. luisarias@telefonica.net
|
